Affordable Access

Access to the full text

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia

  • Boiko, Anastasiia S1
  • Mednova, Irina A1
  • Kornetova, Elena G1, 2
  • Bokhan, Nikolay A1, 3
  • Semke, Arkadiy V1
  • Loonen, Anton J M4
  • Ivanova, Svetlana A1, 3
  • 1 Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk , (Russia)
  • 2 Hospital, Siberian State Medical University, Tomsk , (Russia)
  • 3 Psychiatry, Addictology and Psychotherapy, Siberian State Medical University, Russian Federation , (Russia)
  • 4 PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen
Published Article
Neuropsychiatric Disease and Treatment
Publication Date
Apr 22, 2020
DOI: 10.2147/NDT.S247161
PMID: 32368067
PMCID: PMC7184116
PubMed Central


Background Both dehydroepiandrosterone (DHEAS) and cortisol are secreted by the adrenal glands and may modulate metabolic syndrome (MetS), which often affects the health of patients with schizophrenia. The relationship between the serum levels of these hormones and MetS has not been established. Purpose In this pilot study, we investigated the serum levels in schizophrenia patients with and without MetS and compared them with those in healthy volunteers. Patients and Methods After obtaining informed consent, 110 patients with acute paranoid schizophrenia were recruited directly after admission to the Mental Health Research Institute. The control group consisted of 51 persons reported on questioning to be mentally and somatically healthy. Blood samples to prepare serum were drawn after an 8-h overnight fast during one of the first days of admission. Serum cortisol and DHEAS concentrations were quantified by enzyme-linked immunosorbent assay. Results A total of 42 patients had MetS and 68 patients were without MetS. The cortisol blood level was significantly (p = 0.012) higher in schizophrenia patients without MetS in comparison to healthy controls, while patients with schizophrenia and a MetS have significantly (p = 0.014) lower DHEAS levels than healthy volunteers. These differences could, however, exclusively be attributed to female participants. Analysis of covariance adjusted for gender and age demonstrated a significant relationship between age and DHEAS levels (F = 9.512, р = 0.003). Conclusion Lower DHEAS serum levels in relationship to MetS become evident in women, but not in men, and have age differences as a confounding factor.

Report this publication


Seen <100 times